S.T. Stent

Company Overview

Snapshot

Founded in November 2013 by Joseph Flomenblit, S.T. Stent operates with 1–10 employees. The company has raised $1.76M across four funding rounds from four investors. In July 2024, S.T.

Business overview

S.T. Stent develops composite, removable sinus stents designed for placement in the ethmoid sinus following functional endoscopic sinus surgery. Its core technology aims to keep the cavity open for up to 28 days, improving patient outcomes and reducing the need for revision surgeries. The stent adapts to patient anatomy, is made from biocompatible materials, and can be easily removed in a minimally invasive office procedure. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers globally.

Strategic signal

In June 2022, news highlighted S.T. Stent's revolutionary device for improving sinus surgery outcomes. This signals continued market validation and growing recognition of the company's technology within the medical community, suggesting a positive trajectory for adoption and impact in the surgical device market.

Company Intelligence Q&A

What is S.T. Stent's primary product?

S.T. Stent develops a composite, removable sinus stent designed to be placed in the ethmoid sinus after functional endoscopic sinus surgery to maintain cavity openness for up to 28 days.

When did S.T. Stent receive FDA clearance for its sinus stent?

S.T. Stent was awarded FDA clearance for its sinus stent in January 2018.

When was S.T. Stent founded and by whom?

S.T. Stent was founded in November 2013 by Joseph Flomenblit.